2004年,辉瑞的阿托伐他汀(Lipitor)冲开了100亿美元销售额的关口,成为全球首款百亿美元级别的重磅炸弹。此后经年,Lipitor独领风骚,一直到 2013 年,第2个“百亿美元分子”,艾伯维的阿达木单抗(Humira)诞生。 20年过去了,越来越多的药物加入“百亿美元俱乐部”。根据跨国药企已经披露的2024年财报,去年一年就有11款药物销售超过了100亿美元。加上潜力选手福泰制药的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.